Pediatric rheumatology

Free mycophenolic acid exposure for therapeutic drug monitoring in paediatric lupus nephritis: associations with treatment response and haematologic toxicity

Lupus Sci MedPublished Prospective cohort study

Authors' conclusion

Both t-MPA-AUC and f-MPA-AUC effectively predict MMF efficacy in paediatric LN. However, f-MPA-AUC demonstrates superior predictive value for safety outcomes, specifically haematological ADRs.

Study context

Population
Patients with paediatric lupus nephritis (LN) receiving mycophenolate mofetil (MMF)
Participants
65 patients
Exposure
f-MPA-AUC vs t-MPA-AUC as predictors of treatment response and haematologic toxicity
Outcome
Relapse-free survival and ADR
Follow-up
12 months
Methodological detailspharmacokinetic, ROC analysis, Kaplan-Meier
  • Pharmacokinetic
  • ROC analysis
  • Kaplan-Meier

Main finding

As reported in the abstract

Prediction of relapse-free survival
GroupROC AUCOptimal thresholdAverage remission duration above threshold
t-MPA-AUC0.7031.63 µg·h/mL10.88 months
f-MPA-AUC0.70354.45 ng·h/mL11.00 months

ROC AUC

t-MPA-AUC0.70
f-MPA-AUC0.70

Optimal threshold

t-MPA-AUC31.63 µg·h/mL
f-MPA-AUC354.45 ng·h/mL

Average remission duration above threshold

t-MPA-AUC10.88 months
f-MPA-AUC11.00 months
12-month relapse-free rate
78.7% (95% CI 66.6% to 90.9%)

Observational data: associations, not effects.

Safety

Outcomef-MPA-AUC
Prediction of haematological ADRsIndependently predicted
Optimal threshold492.96 ng·h/mL
Specificity86.2%

MMF-related adverse drug reaction (ADR), overall · 12 months

Overall MMF-related ADR incidence
25.2%
Haematological events, 17
26.2%
Haematological ADR risk factors: t-MPA-AUC, f-MPA-AUC, glucose, β2-microglobulin and C3

Original publication

Free mycophenolic acid exposure for therapeutic drug monitoring in paediatric lupus nephritis: associations with treatment response and haematologic toxicity. Lupus Sci Med. Published 11 August 2026. doi:10.1136/lupus-2026-002091

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.